Información:
Error:
ID
13084
Descripción
Vector Delivery of the IL-12 Gene in Men With Prostate Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00406939
Link
https://clinicaltrials.gov/show/NCT00406939
Palabras clave
Versiones (1)
- 15/1/16 15/1/16 -
Titular de derechos de autor
CC BY-NC 3.0
Subido en
15 de enero de 2016
DOI
Para solicitar uno, por favor iniciar sesión.
Licencia
Creative Commons BY-NC 3.0
Comentarios del modelo :
Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.
Comentarios de grupo de elementos para :
Comentarios del elemento para :
Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.
Eligibility Prostatic Neoplasms NCT00406939
Eligibility Prostatic Neoplasms NCT00406939
- StudyEvent: Eligibility
Similar models
Eligibility Prostatic Neoplasms NCT00406939
- StudyEvent: Eligibility
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de datos
Alias
prostate cancer
Item
men who have biopsy-proven local recurrence or persistence of cancer in the prostate gland with or without metastatic disease after the hormone therapy, cryosurgery, and/or the completion of definitive radiation therapy for at least one year.
boolean
C0600139 (UMLS CUI [1])
patients must have evidence of biologically active local recurrence of tumor as demonstrated by a rising serum psa level on at least 3 separate occasions at least 2 weeks apart, and that the serum psa be below 50 ng/ml.
Item
patients must have evidence of biologically active local recurrence of tumor as demonstrated by a rising serum psa level on at least 3 separate occasions at least 2 weeks apart, and that the serum psa be below 50 ng/ml.
boolean
C0138741 (UMLS CUI [1])
informed consent
Item
the patient will possess the ability to give informed consent and express a willingness to meet all the expected requirements of the protocol for the duration of the study. (informed consent document).
boolean
C0021430 (UMLS CUI [1])
organ function
Item
patients must have adequate baseline organ function as assessed by the following laboratory values before initiating the protocol.
boolean
C0678852 (UMLS CUI [1])
renal function
Item
1. adequate renal function with serum creatinine less than 1.5 mg/dl or creatinine clearance greater than 45 ml/min/m2.
boolean
C0201976 (UMLS CUI [1])
platelets
Item
2. platelet count greater than 100,000 platelets/mm3.
boolean
C0005821 (UMLS CUI [1])
absolute neutrophil count
Item
3. absolute neutrophil count greater than 1000/mm3.
boolean
C0948762 (UMLS CUI [1])
hemoglobin
Item
4. hemoglobin greater than 8.5 mg/dl
boolean
C0019046 (UMLS CUI [1])
ptt and pt
Item
5. normal partial thromboplastin time (ptt) and pro-thrombin time (pt).
boolean
C0030605 (UMLS CUI [1])
liver function
Item
6. bilirubin less than 2.5 mg/dl, sgot and sgpt less than 2.0x normal.
boolean
C1278039 (UMLS CUI [1])
C0201899 (UMLS CUI [2])
C0201836 (UMLS CUI [3])
C0201899 (UMLS CUI [2])
C0201836 (UMLS CUI [3])
infection
Item
acute infection: acute infection is defined as any viral, bacterial or fungal infection, which requires specific therapy.
boolean
C0009450 (UMLS CUI [1])
metastasis
Item
symptomatic metastasis.
boolean
C0027627 (UMLS CUI [1])
metastatic lesions in the cns/spinal cord or organs that could become life or function threatening within 3 months
Item
metastatic lesions in the cns/spinal cord or organs that could become life or function threatening within 3 months.
boolean
C0023671 (UMLS CUI [1])